A Multi-Center Open-Label Evaluation of the Safety of Sarecycline Tablets in the Treatment of Acne Vulgaris
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- David Berk, MD
Allergan, plc
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
56 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Actavis Investigational Study Site #206
Mobile, Alabama, United States
- Actavis Investigational Study Site #236
Hot Springs, Arkansas, United States
- Actavis Investigational Study Site #245
Carlsbad, California, United States
- Actavis Investigational Study Site #129
Encino, California, United States
- Actavis Investigational Study Site #209
Fremont, California, United States
- Actavis Investigational Study Site #147
Sacramento, California, United States
- Actavis Investigational Study Site #125
San Diego, California, United States
- Actavis Investigational Study Site #150
San Diego, California, United States
- Actavis Investigational Study Site #204
San Diego, California, United States
- Actavis Investigational Study Site #222
Denver, Colorado, United States
- Actavis Investigational Study Site #148
Wheat Ridge, Colorado, United States
- Actavis Investigational Study Site #226
Clearwater, Florida, United States
- Actavis Investigational Study Site #238
Jupiter, Florida, United States
- Actavis Investigational Study Site #145
Miami, Florida, United States
- Actavis Investigational Study Site #249
Miami, Florida, United States
- Actavis Investigational Study Site #211
Miramar, Florida, United States
- Actavis Investigation Study Site # 140
North Miami Beach, Florida, United States
- Actavis Investigational Study Site #151
Orange, Florida, United States
- Actavis Investigational Study Site #203
Tampa, Florida, United States
- Actavis Investigational Study Site #242
Snellville, Georgia, United States
- Actavis Investigational Study Site #124
Boise, Idaho, United States
- Actavis Investigational Study Site #106
Chicago, Illinois, United States
- Actavis Investigational Study Site #113
South Bend, Indiana, United States
- Actavis Investigational Study Site #213
Louisville, Kentucky, United States
- Actavis Investigational Study Site #217
Rockville, Maryland, United States
- Actavis Investigational Study Site #251
Clarkston, Michigan, United States
- Actavis Investigational Study Site #235
Clinton Township, Michigan, United States
- Actavis Investigational Study Site #227
Fort Gratiot, Michigan, United States
- Actavis Investigational Study Site #111
Warren, Michigan, United States
- Actavis Investigational Study Site #221
Fridley, Minnesota, United States
- Actavis Investigational Study Site #231
Omaha, Nebraska, United States
- Actavis Investigational Study Site #146
New York, New York, United States
- Actavis Investigational Study Site #208
New York, New York, United States
- Actavis Investigational Study Site #240
Rochester, New York, United States
- Actavis Investigational Study Site #230
Stony Brook, New York, United States
- Actavis Investigational Study Site #229
Raleigh, North Carolina, United States
- Actavis Investigational Study Site #149
Gresham, Oregon, United States
- Actavis Investigational Study Site #257
Philadelphia, Pennsylvania, United States
- Actavis Investigational Study Site #225
Goodlettsville, Tennessee, United States
- Actavis Investigational Study Site #128
Knoxville, Tennessee, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 20 Mar 2015
- Primary completion
- 26 Aug 2016
- Completion
- 26 Aug 2016
- Last update posted
- 1 Feb 2019
- Registered enrollment
- 490
- Registry id
- NCT02413346
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.